{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Andrade C"],"funding":["Conselho Nacional de Desenvolvimento Científico e Tecnológico"],"pagination":["e2720"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6667909"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(1)"],"pubmed_abstract":["Single chain variable fragment-IgGs (scFv-IgG) are a class of bispecific antibodies consisting of two single chain variable fragments (scFv) that are fused to an intact IgG molecule. A common trend observed for expression of scFv-IgGs in mammalian cell culture is a higher level of aggregates (10%-30%) compared to mAbs, which results in lower purification yields in order to meet product quality targets. Furthermore, the high aggregate levels also pose robustness risks to a conventional mAb three column platform purification process which uses only the polishing steps (e.g., cation exchange chromatography [CEX]) for aggregate removal. Protein A chromatography with pH gradient elution, high performance tangential flow filtration (HP-TFF) and calcium phosphate precipitation were evaluated at t"],"journal":["Biotechnology progress"],"pubmed_title":["An Integrated Approach to Aggregate Control for Therapeutic Bispecific Antibodies Using an Improved Three Column Mab Platform-Like Purification Process."],"pmcid":["PMC6667909"],"funding_grant_id":["203023/2014‐5"],"pubmed_authors":["Arnold L","Chung WK","Andrade C","Hunter A","Tang A","Motabar D","Aspelund M"],"additional_accession":[]},"is_claimable":false,"name":"An Integrated Approach to Aggregate Control for Therapeutic Bispecific Antibodies Using an Improved Three Column Mab Platform-Like Purification Process.","description":"Single chain variable fragment-IgGs (scFv-IgG) are a class of bispecific antibodies consisting of two single chain variable fragments (scFv) that are fused to an intact IgG molecule. A common trend observed for expression of scFv-IgGs in mammalian cell culture is a higher level of aggregates (10%-30%) compared to mAbs, which results in lower purification yields in order to meet product quality targets. Furthermore, the high aggregate levels also pose robustness risks to a conventional mAb three column platform purification process which uses only the polishing steps (e.g., cation exchange chromatography [CEX]) for aggregate removal. Protein A chromatography with pH gradient elution, high performance tangential flow filtration (HP-TFF) and calcium phosphate precipitation were evaluated at t","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jan","modification":"2025-04-04T22:08:51.887Z","creation":"2019-08-28T07:01:41Z"},"accession":"S-EPMC6667909","cross_references":{"pubmed":["30298991"],"doi":["10.1002/btpr.2720"]}}